TSS
CRSP icon

Two Sigma Securities’s CRISPR Therapeutics CRSP Stock Holding History

Two Sigma Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,300
Closed -$343K – 1957
2024
Q3 		$343K Sell
7,300
-27,400
-79% -$1.39M 0.01% 1625
2024
Q2 		$1.87M Buy
34,700
+6,600
+23% +$382K 0.02% 742
2024
Q1 		$1.92M Sell
28,100
-23,500
-46% -$1.68M 0.02% 773
2023
Q4 		$3.23M Buy
51,600
+27,000
+110% +$1.49M 0.03% 506
2023
Q3 		$1.12M Buy
24,600
+3,300
+15% +$170K 0.01% 968
2023
Q2 		$1.2M Buy
+21,300
New +$1.21M 0.02% 863
2023
Q1 		– Sell
-14,600
Closed -$593K – 2761
2022
Q4 		$593K Sell
14,600
-9,100
-38% -$483K 0.02% 969
2022
Q3 		$1.55M Buy
23,700
+18,900
+394% +$1.37M 0.05% 450
2022
Q2 		$292K Sell
4,800
-3,000
-38% -$176K 0.01% 1321
2022
Q1 		$490K Buy
+7,800
New +$490K 0.02% 1031
2021
Q3 		– Sell
-3,300
Closed -$534K – 1615
2021
Q2 		$534K Buy
+3,300
New +$401K 0.02% 629

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Securities's CRSP Position: Q3 2023 in Review

Two Sigma Securities sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 6,864 shares — an estimated $354K sold.

Two Sigma Securities first reported a position in CRSP in Q2 2021 and held it in 6 quarters. The position peaked at $687K in Q3 2022. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • Two Sigma Securities reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 6,864 CRISPR Therapeutics shares in Q3 2023, an estimated $354K.
  • Two Sigma Securities first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 6 quarters.
  • Two Sigma Securities's CRISPR Therapeutics position peaked at $687K in Q3 2022.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.